| General Information | |
|---|---|
| ZINC ID | ZINC000040421203 |
| Molecular Weight (Da) | 440 |
| SMILES | Cc1ccccc1[C@@H](c1ccc(Cl)cc1)N1CCN(C(=O)NCC2CCCCC2)CC1 |
| Molecular Formula | C26Cl1N3O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.767 |
| HBA | 1 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| LogP | 6.787 |
| Activity (Ki) in nM | 288.403 |
| Polar Surface Area (PSA) | 35.58 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 0.92037594 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.5 |
| Ilogp | 4.61 |
| Xlogp3 | 5.92 |
| Wlogp | 4.56 |
| Mlogp | 4.62 |
| Silicos-it log p | 4.94 |
| Consensus log p | 4.93 |
| Esol log s | -6.12 |
| Esol solubility (mg/ml) | 0.000332 |
| Esol solubility (mol/l) | 0.00000075 |
| Esol class | Poorly sol |
| Ali log s | -6.44 |
| Ali solubility (mg/ml) | 0.000159 |
| Ali solubility (mol/l) | 0.00000036 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.47 |
| Silicos-it solubility (mg/ml) | 0.0000148 |
| Silicos-it solubility (mol/l) | 3.36E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.78 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.74 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.76 |
| Logd | 4.842 |
| Logp | 5.962 |
| F (20%) | 0.007 |
| F (30%) | 0.455 |
| Mdck | - |
| Ppb | 97.31% |
| Vdss | 1.52 |
| Fu | 0.82% |
| Cyp1a2-inh | 0.09 |
| Cyp1a2-sub | 0.932 |
| Cyp2c19-inh | 0.862 |
| Cyp2c19-sub | 0.932 |
| Cl | 4.554 |
| T12 | 0.057 |
| H-ht | 0.923 |
| Dili | 0.368 |
| Roa | 0.037 |
| Fdamdd | 0.714 |
| Skinsen | 0.038 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.619 |
| Bcf | 1.614 |
| Igc50 | 4.931 |
| Lc50 | 6.165 |
| Lc50dm | 3.772 |
| Nr-ar | 0.022 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.323 |
| Nr-aromatase | 0.018 |
| Nr-er | 0.266 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.006 |
| Sr-are | 0.456 |
| Sr-atad5 | 0.002 |
| Sr-hse | 0.244 |
| Sr-mmp | 0.656 |
| Sr-p53 | 0.635 |
| Vol | 462.563 |
| Dense | 0.95 |
| Flex | 0.28 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.653 |
| Synth | 2.65 |
| Fsp3 | 0.5 |
| Mce-18 | 73.769 |
| Natural product-likeness | -1.373 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |